NEW YORK (GenomeWeb News) – Health Canada has issued a license to SQI Diagnostics allowing the company to market its multiplexed Ig_plex Celiac DGP Panel, the Toronto-based firm said today.
The panel is intended for use in clinical laboratories to help diagnose celiac disease and provides semi-quantitative determination of the IgG and IgA immunoglobulin classes of deamidated gliadin peptide and anti-tissue transglutaminase antibodies in a single test that requires only one human sample, SQI said.
The Ig_plex Celiac DGP Panel runs on the sqid-X system, an automated platform that process hundreds of samples per hour. SQI said that it is filing for regulatory approvals of the panel with "additional jurisdictions."
"This panel will provide clinicians with a valuable and rapid tool to quantify the levels of multiple key biomarkers associated with celiac disease," SQI CEO Andrew Morris said in a statement. "Furthermore, this panel quantifies both peptide biomarkers and antibody biomarkers simultaneously."